1
|
Sasaya T, Kubo T, Murata K, Mizue Y, Sasaki K, Yanagawa J, Imagawa M, Kato H, Tsukahara T, Kanaseki T, Tamura Y, Miyazaki A, Hirohashi Y, Torigoe T. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma. Cancer Med 2023; 12:4605-4615. [PMID: 36200687 PMCID: PMC9972142 DOI: 10.1002/cam4.5310] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 09/07/2022] [Accepted: 09/20/2022] [Indexed: 11/09/2022] Open
Abstract
Immune checkpoint inhibitor-based cancer immunotherapy has provided an additional therapeutic option for oral squamous cell carcinoma (OSCC) with recurrence or distant metastases. However, further improvement of OSCC treatment is required to develop the optimal combination or order for chemoradiotherapy and immunotherapy. Along with the accumulation of clinical knowledge and evidence, it is also essential to clarify the biological impact of chemo-radiotherapeutic agents on the cancer immune microenvironment. In this study, we investigated the effects of cisplatin (CDDP), a key therapeutic agent for OSCC, on programmed death-ligand 1 (PD-L1) expression in OSCC lines. Although CDDP treatment increased the surface levels of PD-L1 on OSCC cell lines, the gene and total protein expression levels of PD-L1 were not altered. We also demonstrated that the phosphorylation of heat shock factor 1 and heat shock protein 90 was involved in this process. In addition, CDDP-induced PD-L1 attenuated the target-specific cytotoxic T lymphocyte reaction to OSCC. These results provide an immunobiological basis for the response of OSCC to CDDP and will contribute to our biological understanding of the action of novel combination therapy including immunotherapy together with platinum-based chemotherapy for OSCC.
Collapse
Affiliation(s)
- Takashi Sasaya
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan.,Department of Oral Surgery, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Terufumi Kubo
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Kenji Murata
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Yuka Mizue
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Kenta Sasaki
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Junko Yanagawa
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Makoto Imagawa
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Hirotaka Kato
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan.,Department of Oral Surgery, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Tomohide Tsukahara
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Takayuki Kanaseki
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Yasuaki Tamura
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Akihiro Miyazaki
- Department of Oral Surgery, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Yoshihiko Hirohashi
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| | - Toshihiko Torigoe
- Department of Pathology, Sapporo Medical University, School of Medicine, Sapporo, Japan
| |
Collapse
|